Serotonergic and sympatho-adrenal systems in heart failure: An old but still alive pathway

Cardiology

Volumn 113, Issue 4, 2009, Pages 274-276

  Tousoulis, Dimitris ^a   Papageorgiou, Nikos ^a   Tentolouris, Costas ^a   Stefanadis, Christodoulos ^a  

^a UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

Author keywords

[No Author keywords available]

Indexed keywords

5 HYDROXYINDOLEACETIC ACID; ADRENALIN; AROMATIC LEVO AMINO ACID DECARBOXYLASE; DOPAMINE; ISOPRENALINE; NORADRENALIN; SEROTONIN; SEROTONIN 2B RECEPTOR; SEROTONIN NORADRENALIN REUPTAKE INHIBITOR; SEROTONIN UPTAKE INHIBITOR;

ADRENAL GLAND; ADRENALIN BLOOD LEVEL; ADRENERGIC SYSTEM; CONGESTIVE HEART FAILURE; CORONARY ARTERY DISEASE; DRUG TARGETING; HEART FAILURE; HEART HYPERTROPHY; HEART LEFT VENTRICLE HYPERTROPHY; HUMAN; NORADRENALIN BLOOD LEVEL; NORADRENALIN RELEASE; NOTE; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROGNOSIS; SEROTONINERGIC SYSTEM; THROMBOCYTE;

ADRENAL GLANDS; HEART FAILURE; HUMANS; SEROTONIN; SYMPATHETIC NERVOUS SYSTEM;

EID: 61449197793     PISSN: 00086312     EISSN: None     Source Type: Journal    
DOI: 10.1159/000205961     Document Type: Note

References (11)

1. Bolger A, Sharma R, Li W, Leenarts M, Kalra PR, Kemp M, Coats AJ, Anker SD, Gatzoulis MA:Neurohormonal activation and the chronic heart failure syndrome in adults with congenital heart disease. Circulation 2002;106:92-99.
2. CôtéF, Fligny C, Fromes Y, Mallet J, Vodjdani G:Recent advances in understanding serotonin regulation of cardiovascular function. Trends Mol Med 2004;10:232-238.
3. Deuchar GA, Hicks MN, Cobbe SM, Docherty CC, MacLean MR:Pulmonary responses to 5-hydroxytryptamine and endothelin-1 in a rabbit model of left ventricular dysfunction. Cardiovasc Res 1998;38:500-507.
4. 2B receptor in heart leads to abnormal mitochon-drial function and cardiac hypertrophy. Circu lation 2003;107:3223 -3229.
5. Tousoulis D, Antoniades C, Drolias A, Stefanadi E, Marinou K, Vasiliadou C, Tsioufis C, Toutouzas K, Latsios G, Stefanadis C:Selective serotonin reuptake inhibitors modify the effect of beta-blockers on long-term survival of patients with end-stage heart failure and major depression. J Card Fai l 2008;14:456-464.
6. Cohn JN, Levine TB, Olivari MT, Garberg V, Lura D, Francis GS, Simon AB, Rector T:Plasma norepinephrine as a guide to prognosis in patients with chronic congestive heart failure. N Engl J Med 1984;311:819-823.
7. Tsutamoto T, Nishiyama K, Sakai H, Tanaka T, Fuji i M, Ya mamoto T, Yamaji M, Horie M:Transcardiac increase in norepinephrine and prognosis in patients with chronic heart failure. Eur J Heart Fail 2008;10:1208-1214.
8. Corea L, Bentivoglio M, Verdecchia P, Motolese M:Plasma norepinephrine and left ventricular hypertrophy in systemic hypertension. Am J Cardiol 1984;53:1299-1303.
9. Sabbah HN, Stanley WC, Sharov VG, Mishi-ma T, Tanimura M, Benedict CR, Hegde S, Goldstein S:Effects of dopamine beta-hy-droxylase inhibition with nepicastat on the progression of left ventricular dysfunction and remodeling in dogs with chronic heart failure. Circulation 2000;102:1990-1995.
10. Asakura S, Tabei K, Muto S, Asano Y, Hosoda S:The role of endogenous dopamine in congestive heart failure. Jpn Heart J 1989;30:115-127.
11. Nigmatullina RR, Kirillova VV, Jourjikiya RK, Mukhamedyarov MA, Kudrin VS, Klodt PM, Palotás A:Disrupted serotonergic and sympatho adrenal systems in patients with chronic heart failure may serve as new therapeutic targets and novel biomarkers to assess severity, progression and response to treatment. Cardiology 2009;113:277-286.